Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

Bibliography

• European Commission Health and Consumers Directorate-General—Directorate C—Public Health and Risk Assessment: estimated number of people with dementia. Available from: http://ec.europa.eu/health/ph_information/dissemination/echi/docs/dementia2_en.pdf(2006) [Accessed January 2012]
   Google Scholar
• Wimo A, Jonsson L, Gustavsson A, et al. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 2011;26(8):825-32
   PubMed Web of Science ®Google Scholar
• Matthews F, Brayne C. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. PLoS Med 2005;2:e193
   PubMed Web of Science ®Google Scholar
• Miller EA, Schneider LS, Zbrozek A, Rosenheck RA. Sociodemographic and clinical correlates of utility scores in Alzheimer's disease. Value Health 2008;11:1120-30
   PubMed Web of Science ®Google Scholar
• Wlodarczyk JH, Brodaty H, Hawthorne G, et al. The relationship between quality of life, Mini-Mental State Examination, and the Instrumental Activities of Daily Living in patients with Alzheimer's disease. Arch Gerontol Geriatr 2004;39:25-33
   PubMed Web of Science ®Google Scholar
• Andersen CK, Wittrup-Jensen KU, Lolk A, et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2004;2:52
   PubMedGoogle Scholar
• Karlawish JH, Zbrozek A, Kinosian B, et al. Caregivers' assessments of preference-based quality of life in Alzheimer's disease. Alzheimers Dement 2008;4:203-11
   PubMed Web of Science ®Google Scholar
• Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a metaanalysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24(1):20-7
   PubMed Web of Science ®Google Scholar
• Heinen-Kammerer T, Rulhoff H, Nelles S, et al. Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease. Clin Drug Investig 2006;26(6):303-14
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011;68(8):991-8
   PubMed Web of Science ®Google Scholar
• Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer's disease. Int J Geriatr Psychiatry 2012;27(8):769-76
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3):317-24
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5(1):83-9
   PubMed Web of Science ®Google Scholar
• Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharm Des 2004;10:231-51
   PubMed Web of Science ®Google Scholar
• Racchi M, Mazzucchelli M, Porrello E, et al. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004;50:441-51
   PubMed Web of Science ®Google Scholar
• Jelic V, Darreh-Shori T. Donepezil: a review of pharmacological characteristics and role in the management of Alzheimer disease. Clin Med Insights: Ther 2010;2:771-88
   Google Scholar
• Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol 2005;1:527-36
   PubMedGoogle Scholar
• Rodríguez JJ, Noristani HN, Verkhratsky A. The serotonergic systém in ageing and Alzheimer's disease. Prog Neurobiol 2012;99:15-41
   PubMed Web of Science ®Google Scholar
• Cheung J, Rudolph MJ, Burhsteyn F, et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012;55:10282-6
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Yamanishi Y, Iimura Y, et al. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 2000;7:303-39
   PubMed Web of Science ®Google Scholar
• Bartolini M, Bertucci C, Cavrini V, et al. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003;65:407-16
   PubMed Web of Science ®Google Scholar
• Inestrosa N, Alvarez A, Perez C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881-91
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. FEBS J 2008;275:625-32
   PubMed Web of Science ®Google Scholar
• Rees T, Hammond PI, Soreq H, et al. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neuorbiol Aging 2003;24:777-87
   PubMed Web of Science ®Google Scholar
• DeLano WL. The PyMOL molecular graphics system. DeLano Scientific; San Carlos, CA; 2012
   Google Scholar
• Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 2005;26:104-11
   PubMed Web of Science ®Google Scholar
• Akasofu S, Kosasa T, Kimura M, Kubota A. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol 2003;472(1-2):57-63
   PubMed Web of Science ®Google Scholar
• Shen H, Kihara T, Hongo H, et al. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of α7 nicotinic receptors and internalization of NMDA receptors. Br J Phamracol 2010;161:127-39
   PubMed Web of Science ®Google Scholar
• Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport 1998;9:1519-22
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Richardson S, Relkin N. Challenges and opportunities—Lessons from donepezil therapy. Alzheimers Dement 2008;4:109-18
   Web of Science ®Google Scholar
• Robertson IH. A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease. Neurobiol Aging 2013;34:298-308
   PubMed Web of Science ®Google Scholar
• Trillo L, Das D, Hsieh W, et al. Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care. Neuroscience 2013;37:1363-79
   Web of Science ®Google Scholar
• Čolović MB, Krstić DZ, Lazarević-Pašti TD, et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013;1:315-35
   Google Scholar
• Aricept Product monography EISAI/Pfizer 1999
   Google Scholar
• Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother 2009;9:591-8
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Washington, DC. Available from: http://www.clinicaltrials.gov/ct2/results?term=donepezil [Last accessed 12 November 2013]
   Google Scholar
• Müller T. Rivastigmine in the treatment of patients with Alzheimer´s disease. Neuropsychiatr Dis Treat 2007;3(2):211-18
   PubMedGoogle Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer´s disease. Clin Ther 1998;20(4):634-47
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59(4):563-72
   PubMed Web of Science ®Google Scholar
• Rokonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular form in normal and Alzheimer´s disease brain. Acta Biol Hung 2003;54(2):183-9
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Vijayaraghavan S, Aeinehband S, et al. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer´s disease. Neurobiol Aging 2013;34(11):2465-81
   PubMed Web of Science ®Google Scholar
• Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer´s disease: an update. Clin Interv Aging 2007;2(1):17-32
   PubMed Web of Science ®Google Scholar
• Guillzet AL, Smiley JF, Mash DC, Mesulam M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42(6):909-18
   PubMed Web of Science ®Google Scholar
• Mesulam M, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-7
   PubMed Web of Science ®Google Scholar
• Stefanova E, Blennow K, Almkvist O, et al. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42/CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer´s disease (AD) patients. Neurosci Lett 2003;338:159-63
   PubMed Web of Science ®Google Scholar
• Bailey J, Ray B, Greig N, et al. Rivastigmine lowers Abeta and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011;6(7):e21954
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley EJ, Iakovidou V, et al. Rivastigmine for Alzheimer´s disease. Cochrane Database Syst Rev 2009(2):CD001191
   PubMed Web of Science ®Google Scholar
• Cummings JL, Farlow MR, Meng X, et al. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in atients with mild-to-moderate Alzheimer´s disease. Clin Drug Investig 2010;30(1):41-9
   PubMed Web of Science ®Google Scholar
• Farlow MR, Grossberg GT, Sadowsky CH, et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24h versus 4.6mg/24h in severe Alzheimer´s dementia. CNS Neurosci Ther 2013;19(10):745-52
   PubMed Web of Science ®Google Scholar
• Grossberg G, Cummings J, Frölich L, et al. Efficacy if higher dose 13.3 mg/24h rivastigmine patch on instrumentál activities of daily living in patients with mild-to-moderate Alzheimer´s disease. Am J Alzheimers Dis Other Demen 2013;28:583-91
   PubMed Web of Science ®Google Scholar
• Priano L, Gasco ML, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006;23(5):357-75
   PubMed Web of Science ®Google Scholar
• Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008;83(1):106-14
   PubMed Web of Science ®Google Scholar
• Winblad B, Grossberg G, Frohlich L, et al. IDEAL: a 6-month, doble-blind, placebo-controlled study of the first skin patch for Alzheimer´s disease. Neurology 2007;69(4):S14-22
   PubMedGoogle Scholar
• Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamics drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000;15:242-7
   PubMed Web of Science ®Google Scholar
• Enz A, Gartsch C. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 2004;47(3):408-23
   PubMed Web of Science ®Google Scholar
• Barton DHR, Kirby GW. Phenol oxidation and biosynthesis. Part V. The synthesis of galanthamine. J Chem Soc 1962;806-17
   Web of Science ®Google Scholar
• Marco-Contelles J, do Carmo Carreiras M, Rodriguez C, et al. Synthesis and pharmacology of Galanthamine. Chem Rev 2006;106(1):116-33
   PubMed Web of Science ®Google Scholar
• Mashkovskii MD. Effects of galantamine on the acetylcholine sensitivity of skeletal musculature. Pharmacol Toxicol 1955;18:18-21
   Google Scholar
• Jann MW, Shidey KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-39
   PubMed Web of Science ®Google Scholar
• Woodruff-Pak D, Lander C, Geerts H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 2002;8:405-26
   PubMedGoogle Scholar
• Huang F, Fu Y. A review of clinical pharmacocinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer´s disease, in healthy subject and patients. Curr Clin Pharmacol 2010;5:115-24
   PubMedGoogle Scholar
• Greenblatt HM, Kryger G, Lewis T, et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett 1999;463:321-6
   PubMed Web of Science ®Google Scholar
• Samochodski M, Höffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024-36
   PubMed Web of Science ®Google Scholar
• Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer´s disease. Eur J Pharmacol 2000;393:165-70
   PubMed Web of Science ®Google Scholar
• Ago Y, Koda K, Ota Y, et al. Donepezil, but not galanthamine, blocs muscarinic receptor-mediated in vitro and in vivo responses. Synapse 2011;65:1373-7
   PubMed Web of Science ®Google Scholar
• Coyle J, Kershaw P. Galanthamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer´s disease. Biol Psychiatry 2001;49:289-99
   PubMed Web of Science ®Google Scholar
• Moriguchi S, Marszalec W, Zhao X, et al. Mechanism of action of galanthamine on N-methyl-D-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 2004;310:933-42
   PubMed Web of Science ®Google Scholar
• Takada-Takatori Y, Kume T, Izumi Y, et al. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induces neuroprotection and nicotinic receptor up-regulation. Biol Pharm Bull 2009;32:318-24
   PubMed Web of Science ®Google Scholar
• Simoni E, Daniele S, Bottegoni G, et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J Med Chem 2012;55:9708-21
   PubMed Web of Science ®Google Scholar
• Lopes JP, Tarozzo G, Reggiani A, et al. Galantamione potentiates the neuroprotectibe effect of memantine against NMDA-induces excitotoxicity. Brain Behav 2013;3:67-74
   PubMedGoogle Scholar
• Matharu B, Gibson G, Parsons R, et al. Galantamine inhibits beta-amyloid aggregation and cytotoxicity. J Neurol Sci 2009;280:49-58
   PubMed Web of Science ®Google Scholar
• Dineley KT, Westerman M, Bui D, et al. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha 7 nicotinic acetylcholine receptors: in vitro and in vivo mechanism related to Alzheimer´s disease. J Neurol Sci 2001;21:4125-33
   Google Scholar
• Melo JB, Sousa C, Garcao P, et al. Galanthamine prospects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci 2009;29:455-64
   PubMed Web of Science ®Google Scholar
• Triana-Vidal LE, Carvajal-Varona SM. Protective effect of galantamine against oxidative damage using human lymphocytes: a novel in vitro model. Arch Med Res 2013;44:85-92
   PubMed Web of Science ®Google Scholar
• Hellström-Lindahl E, Moore H, Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 2001;74:777-84
   Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, et al. Galanthamine in AD: a 6-month randomized, placebo-controlled trial with 6-month extension. The Galanthamine USA-1 Study Group. Neurology 2000;54:2261-8
   PubMed Web of Science ®Google Scholar
• Seltzer B. Galantamine-ER for th treatment of mild-to- moderate Alzheimer´s disease. Clin Interv Aging 2010;5:1-6
   PubMed Web of Science ®Google Scholar
• Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excresion of galantamine in rats, dogs, and humans. Drug Metab Dispos 2002;30:553-63
   PubMed Web of Science ®Google Scholar
• Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimer´s disease. Expert Opin Drug Metab Toxicol 2010;6:1-10
   PubMed Web of Science ®Google Scholar
• Shi J, Seltzer B. Galantamine: an update. Neurodegen Dis Manage 2011;1:227-34
   Google Scholar
• Rutter AR, Freeman FM, Stephenson FA. Further characterization of the molecular interaction between PSD-95 and NMDA receptors: the effect of the NR1 splice variant and evidence for modulation of channel gating. J Neurochem 2002;81:1298-307
   PubMed Web of Science ®Google Scholar
• Olivares DK, Deshpande V, Shi YK, et al. Nmethyl d-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimers disease, vascular dementia and Parkinsons disease. Curr Alzheimer Res 2012;9:746-58
   PubMed Web of Science ®Google Scholar
• Wolosker H, Radzishevsky I. The serine shuttle between glia and neurons: implications for neurotransmission and neurodegeneration. Biochem Soc Trans 2013;41(6):1546-50
   PubMedGoogle Scholar
• Reiser G, Binmöller FJ, Koch R. Memantine (1-amino-3,5-dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Res 1988;443(1-2):338-44
   PubMed Web of Science ®Google Scholar
• Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001;306(1-2):81-4
   PubMed Web of Science ®Google Scholar
• Buisson B, Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53(3):555-63
   PubMed Web of Science ®Google Scholar
• Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J pharmacol Exp Ther 2005;312(3):1195-205
   PubMed Web of Science ®Google Scholar
• Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse 2008;62(2):149-53
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-97
   PubMed Web of Science ®Google Scholar
• Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 2013;346:f2914
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on indirect treatment comparisons good research practices–part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on indirect treatment comparisons good research practices–part 2. Value Health 2011;14:429-37
   PubMed Web of Science ®Google Scholar
• Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess 2012;16(21):1-470
   PubMed Web of Science ®Google Scholar
• Cumbo E. Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial. Prim Care Community Psychiatr 2005;10:95-102
   Google Scholar
• Fuschillo C, La Pia S, Campana F, et al. Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents. Arch Gerontol Geriatr 2001;33:151-8
   PubMedGoogle Scholar
• Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-6
   PubMed Web of Science ®Google Scholar
• Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:58-67
   PubMed Web of Science ®Google Scholar
• Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6:4-14
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Amatniek J, Ascher S, et al. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis Assoc Disord 2005;19:240-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.consort-statement.org/ [Assessed on 20 Januray 2014]
   Google Scholar
• Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculper MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edition. Oxford; University Press; 2005. ISBN 978-019-852945-3
   Google Scholar
• Kobelt G. Health economics: an introduction to economic evaluation. 3rd edition. Office of Health Economics; 2013. ISBN 978-1-899040-44-5
   Google Scholar
• McGregor M, Caro JJ. QALYs: are they helpful to decision makers? Pharmacoeconomics. Springer; 2006;24(10):947-52
   Google Scholar
• Bar-on P, Millard CB, Harel M, et al. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002;41:3555-64
   PubMed Web of Science ®Google Scholar